Latest news with #Cramer
CNBC
5 hours ago
- Business
- CNBC
Jim Cramer explains why Johnson & Johnson rallied after 'surprise' earnings results
As Wall Street navigates a jam-packed start to earnings season, CNBC's Jim Cramer explained what made shares of Johnson & Johnson rise after the company posted its quarterly report. "Sometimes in this game, you do just get lucky," he said. "You'll come across a surprise quarter that tells you everything you need to know about what can cause a big cap stock to rally ten points in a session. You'll see how a star is born and even get a blueprint for what you need, what you should be looking for." Stock of the pharmaceutical giant climbed more than 6% during Wednesday's session after it beat on earnings and revenue. Cramer said the "storied company" has been weighed down for years by ongoing lawsuits that allege its talc products cause cancer. According to Cramer, it took "many surprises" to spur Johnson & Johnson's gains. He told investors it's worthwhile to review an "earnings scorecard slash schematic of what a winner looks like." Some fundamental data from the quarter helped fuel Johnson & Johnson's rally, Cramer said. The company beat on earnings and sales, and it managed to significantly raise guidance for both metrics. He also said pharma names like Johnson & Johnson need to relay breakthroughs in research — and the drug maker was able to share promising results from one of its newer cancer treatments. Right now, good news on the tariff front is attractive to investors, Cramer continued. He pointed out that Johnson & Johnson was able to cut its previous estimates for costs related to the new duties. Wall Street also appreciates when a new quarter shows that a previous issue has been remedied, Cramer said. Johnson & Johnson's med-tech division dragged shares down after the last quarter, he suggested. But this time, he said, the business didn't disappoint. Johnson & Johnson also impressed Wall Street with projections for the future, Cramer added, highlighting management's lofty assertion on the call that it would be "the number one oncology company by 2030 with sales of more than $50 billion." Cramer noted that the company announced a breakthrough in bladder cancer treatment that could be worth $5 billion in peak sales. "Check your stocks. Do they have a chance to change their stripes like J&J? Do they fit the formula?" he asked. "Then, you know what, you may be just sitting on – say it with me – a gold mine." Johnson and Johnson did not immediately respond to request for comment. Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest
Yahoo
17 hours ago
- Business
- Yahoo
Jim Cramer Says PepsiCo is Too Cheap Yet Overlooked
PepsiCo, Inc. (NASDAQ:PEP) is one of the stocks that Jim Cramer shared insights on. Cramer discussed the stock's valuation during the episode, as he said: 'If you want to know a stock that's too cheap relative to its growth rate, but nobody talks about it anymore, why don't you check out the stock of PepsiCo? It trades at a stunningly low 17 times earnings. I mean, what gives? Well, how about GLP-1 drugs? How about RFK Junior at Health and Human Services, who despises junk food even as he seems to embrace junk science? How about the desire to stay healthy? All these have weighed on PepsiCo stock. Of course, don't forget they own Frito-Lay. Maybe it's finally overdone. I don't know it. It's a tough industry all of a sudden.' A close up of a glass of a refreshing carbonated beverage illustrating the company's different beverages. PepsiCo (NASDAQ:PEP) produces and sells a wide range of beverages and packaged foods, including snacks, cereals, dairy products, and soft drinks. The company's portfolio features well-known brands like Lay's, Gatorade, Quaker, and Pepsi. While we acknowledge the potential of PEP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
17 hours ago
- Business
- Yahoo
Jim Cramer Warns Netflix Faces High Bar
Netflix, Inc. (NASDAQ:NFLX) is one of the stocks that Jim Cramer shared insights on. During the episode, Cramer emphasized the company's need to post good earnings. He remarked: 'After the close, we're treated to the most delightful of conference calls, Netflix. First thing, I have a dearth of things to watch right now. It's really starting to bug me. So I'm going to be listening to the conference call in part because they talk about all the great overseas programming. I get some terrific ideas of what to watch when I get home that night. The bar is very high for Netflix, though, which will have to tell us how their ad tier is going, how Squid Game did, and how NFL Christmas streaming football advertising's looking. A home theater with family members enjoying streaming content together. Netflix (NASDAQ:NFLX) provides streaming entertainment, including TV series, films, documentaries, and games across multiple genres and languages. While we acknowledge the potential of NFLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
17 hours ago
- Business
- Yahoo
Jim Cramer on Abbott: 'Patience is a Virtue With ABT'
Abbott Laboratories (NYSE:ABT) is one of the stocks that Jim Cramer shared insights on. While discussing the stock, Cramer recommended patience, as he commented: 'Then one of my absolute favorite companies, medical device maker, Abbott Labs reports. And you know, I always like to tell you which companies tend to be misinterpreted in a negative way during the earnings season. Abbott's a textbook example. It bothers me, but there are always sellers who claim to be disappointed. So, if you don't own any Abbott, may I suggest that you wait to see the numbers, wait for the stock's opening, wait for the sellers to appear. Patience is a virtue with ABT.' An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Abbott Laboratories (NYSE:ABT) develops and sells healthcare products, including pharmaceuticals, diagnostics, medical devices, and nutritional items. The company's products address conditions in areas like cardiovascular health, diabetes, infectious diseases, and chronic pain management. During a May episode, Cramer mentioned the stock and said: 'Okay, their forward PE shows that there's going to be a, pretty much of an earnings explosion. And I think a lot of that's going to be coming from Libre, which is their diabetes, they have the best diabetes device. It's cheaper than everybody's. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 hours ago
- Business
- Yahoo
Jim Cramer on American Express: 'It's Prized'
American Express Company (NYSE:AXP) is one of the stocks that Jim Cramer shared insights on. Cramer noted that the stock usually falls off after earnings. He commented: 'Then on Friday, there's American Express, which is another stock that tends to sell off when it reports, no matter how good the numbers are. That's why I always tell you to wait until the selling subsides if you want in this time… I don't know what they're thinking about, the sellers… They've been wrong for 150 points. Look at that stock. Listen to the call. A close-up view of a payment terminal, capturing the sophistication of a payment network. American Express (NYSE:AXP) provides credit cards, banking, payment solutions, and travel services to consumers and businesses. The company also offers merchant services, loyalty programs, fraud prevention, and expense management tools. While we acknowledge the potential of AXP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
